Skip to main content

Advertisement

Log in

Paradoxical changing of serum p53 antibody titers during chemotherapy for a stage IV esophageal squamous cell carcinoma

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Long-term monitoring of serum p53 antibody (s-p53-Ab) in patients with advanced cancer during chemotherapy has not been reported. Particularly, very few information was available during the last phase of patient’s life. We report s-p53-Ab changing during chemotherapy for 3 years in a 60-year-old man with stage IV (T2N3M1) esophageal squamous cell carcinoma till the end of his life. s-p53-Ab decreased after first-line chemotherapy and the tumor gradually shrank and stabilized over 6 months. Second-line chemotherapy with docetaxel was initiated after tumor regrowth, followed by third-line chemotherapy with docetaxel and nedaplatin after subsequent regrowth. s-p53-Ab decreased again with treatment response after the second regrowth of the tumor. During the last phase of life, s-p53-Ab did not increase and was not associated with tumor load.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Shimada H, Ochiai T (2007) Molecular diagnosis and treatment for esophageal carcinoma with p53. Esophagus 4:165–168

    Article  Google Scholar 

  2. Kato H, Nakajima M, Fukuchi M (2005) Serum p53 antibodies in drainage blood from the azygos vein in patients with esophageal carcinoma. Anticancer Res 25:3231–3235

    PubMed  CAS  Google Scholar 

  3. Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683

    Article  PubMed  CAS  Google Scholar 

  4. Shimada H, Nagata M, Cho A et al (2013) Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. doi:10.1007/s00595-013-0787-y

    PubMed Central  Google Scholar 

  5. Shimada H, Nabeya Y, Okazumi S et al (2000) Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 132:41–47

    Article  Google Scholar 

  6. Takahashi K, Miyashita M, Nomura T et al (2007) Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus 20:117–122

    Article  PubMed  CAS  Google Scholar 

  7. Shimada H, Shiratori T, Takeda A et al (2009) Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 33:272–277

    Article  PubMed  Google Scholar 

  8. Japanese Society for Esophageal Diseases (2007) Guidelines for the clinical and pathologic studies on carcinoma of the esophagus, 10th edn. Kanehara, Tokyo

    Google Scholar 

  9. Shimada H, Ochiai T, Nomura F (2003) Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682–689

    Article  PubMed  Google Scholar 

  10. Shimada H, Yajima S, Oshima Y et al (2012) Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus 9:131–140

    Article  Google Scholar 

  11. Cai HY, Wang XH, Tian Y et al (2008) Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma. World J Gastroenterol 14:4082–4086

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Shimada H, Okazumi S, Takeda A et al (2001) Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today 31:591–596

    Article  PubMed  CAS  Google Scholar 

  13. Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133:24–31

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiedaki Shimada.

About this article

Cite this article

Shimada, H., Nagata, M., Nabeya, Y. et al. Paradoxical changing of serum p53 antibody titers during chemotherapy for a stage IV esophageal squamous cell carcinoma. Int Canc Conf J 3, 232–236 (2014). https://doi.org/10.1007/s13691-014-0153-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-014-0153-y

Keywords

Navigation